Kexing Biopharm Co., Ltd.

Clinical trials sponsored by Kexing Biopharm Co., Ltd., explained in plain language.

Kexing Biopharm Co., Ltd. 688136 SSE

A Chinese biopharmaceutical company developing vaccines and biological products.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Inhaled interferon could be new weapon against severe RSV in young children Results expected Jun 2027 (estimated) 🚀 Make-or-break

Browse trials soon ready across all sponsors →

Trials to join now! 3 Not yet finished but already full! 1

New shot could shield breast cancer patients from Chemo's dangerous side effect

Prevention Ongoing

This phase 3 trial tests a long-acting injection called PEG-G-CSF to prevent severe neutropenia (dangerously low white blood cell counts) after chemotherapy in 250 women with breast cancer. Participants receive either the test drug or the already-approved Neulasta. The goal is to…

Phase 3 • Sponsor: Kexing Biopharm Co., Ltd. • Aim: Prevention

Last updated Jun 27, 2026 07:59 UTC

Kexing Biopharm Co., Ltd.

Upcoming readouts

New shot could shield breast cancer patients from Chemo's dangerous side effect